ImmunoMet
is a Texas-based biotechnology company that develops and commercializes therapies for the treatment of cancer and fibrosis diseases... Read moreImmunoMet
is a Texas-based biotechnology company that develops and commercializes therapies for the treatment of cancer and fibrosis diseases... Read more
2008
PrivateIndependent Company
News
Jan 30, 2025
Korea Newswire
Press Release: ImmunoMet : ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting
Nov 18, 2022
Korea Newswire
Press Release: ImmunoMet : ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
Jul 26, 2021
MarketScreener
ImmunoMet: Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer
May 03, 2021
MarketScreener
ImmunoMet: ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis
Feb 09, 2021
Korea Newswire
Press Release: ImmunoMet : ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
Feb 08, 2021
BioSpace
ImmunoMet: ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
Feb 16, 2018
cfomoves
ImmunoMet: ImmunoMet Therapeutics [HOUSTON] announced the appointment of Allan J. Shaw as Chief Financial Officer
Nov 29, 2017
Post Online Media
ImmunoMet: ImmunoMet Therapeutics appoints two directors
Oct 03, 2017
BioSpace
ImmunoMet: ImmunoMet Therapeutics Announces Initiation Of Phase I Clinical Study Of IM156, An OXPHOS Inhibitor, In Patients With Solid Tumors
Mar 16, 2017
BioPortfolio
ImmunoMet: ImmunoMet Raises $5M in Series B Financing
